Crucell Teams up with ACE BioSciences and Harvard to Accelerate Bacterial Antibody Program
02. November 2005 02:12 ET
|
Crucell N.V.
LEIDEN, Netherlands, Nov. 02, 2005 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) announced today that it has licensed bacterial antigens from ACE BioSciences...
Galapagos Featured in Leading Drug Discovery Journal
14. Oktober 2005 02:07 ET
|
Galapagos Genomics
MECHELEN, Belgium, Oct. 14, 2005 (PRIMEZONE) -- Galapagos NV, a genomics-based drug discovery company, announces that an article presenting the Company's approach to target discovery will appear in...
Active Biotech: Confirmed ANYARA Tumor PET Localization in Cancer Patients
30. September 2005 02:35 ET
|
Active Biotech
STOCKHOLM, Sweden, Sept. 30, 2005 (PRIMEZONE) -- In an ongoing clinical Phase I study, specific tumor localization of Active Biotech's candidate drug ANYARA, has now been objectively confirmed.Using...
Crucell Appoints Agents to Boost Asian Market Potential
20. September 2005 02:06 ET
|
Crucell N.V.
LEIDEN, Netherlands, Sept. 20, 2005 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) announced today that it has entered into agreements with Pharma&Soft in...